EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Characterization of recombinant factor IX fusion proteins enabling subcutaneous administration

Kathrin Schön, Sabine Pestel, Julia Riedesel, Waltraud Seyfert-Brandt, Philipp Claar, Eva Herzog, Alireza Rezvani-Sharif, Padmapriya Ponnuswamy, Marc W Nolte

Journal of Thrombosis and Haemostasis · 2024

DOI: 10.1016/j.jtha.2024.07.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Kathrin Schön und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology & Toxicology, Research, CSL Innovation GmbH, Marburg, Hesse, Germany; Institute of Pharmacology, Biochemical-Pharmacological Center, Uni…. Hauptthemen laut MEDLINE: Factor IX, Hemophilia B, Recombinant Fusion Proteins. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The X-linked bleeding disorder hemophilia B, caused by mutation(s) in the coagulation factor (F)IX gene, leads to partial or total loss of its function, requiring lifelong FIX replacement therapy. Although new recombinant FIX (rIX) therapeutics like albumin fusion proteins (rIX-FP) enable longer plasma half-life and thus less frequent administration, the complexity of intravenous (i.v.) injection remains. OBJECTIVES: The study aimed to characterize rIX-FP variants with anticipated enhanced specific activity, which would leverage rIX-FP's superior pharmacokinetic profile with beneficial characteristics for subcutaneous (s.c.) administration. METHODS: Two rIX-FP variants, R338L ("Padua variant") and R338L/E410K, were characterized in vitro. Pharmacokinetic profiles of FIX antigen and activity levels were evaluated in FIX-deficient mice after i.v. and s.c. administration of these variants (dosing based on antigen levels). The efficacy of the most promising variant was tested after i.v. and s.c. administration (dosing based on activity) in a tail clip bleeding model. A marketed wild-type (WT) rIX-FP product served as the comparator. RESULTS: Both rIX-FP variants showed a 4- to 5-fold increase in specific activity in vitro compared with rIX(WT)-FP, while FXIa-mediated activation was the fastest for rIX(WT)-FP and rIX(R338L)-FP. Compared with rIX(WT)-FP and rIX(R338L/E410K)-FP, rIX(R338L)-FP exhibited higher FIX activity exposure after i.v. and s.c. administration and demonstrated comparable efficacy with rIX(WT)-FP in reducing bleeding time and blood loss in FIX-deficient mice requiring ∼4 times lower protein amount. CONCLUSION: rIX(R338L)-FP was shown to be a promising candidate for s.c. administration, exhibiting increased specific activity combined with higher activity-based exposure and indicating efficacy at a lower protein dose.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor IXHemophilia BRecombinant Fusion ProteinsAnimalsHumansMaleMiceCoagulantsDisease Models, AnimalHalf-LifeHemorrhageInjections, IntravenousInjections, SubcutaneousMice, Inbred C57BLMice, KnockoutMutation

Stichwörter der Autor:innen

factor IXfactor IX-Paduahemophilia Brecombinant fusion proteins

Substanzen

CoagulantsFactor IXRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Pharmacology & Toxicology, Research, CSL Innovation GmbH, Marburg, Hesse, Germany; Institute of Pharmacology, Biochemical-Pharmacological Center, University of Marburg, Marburg, Hesse, Germany.
  • Pharmacology & Toxicology, Research, CSL Innovation GmbH, Marburg, Hesse, Germany.
  • Recombinant Protein Expression, Research, CSL Innovation GmbH, Marburg, Hesse, Germany.
  • Pharmacology & Toxicology, Research, CSL Behring LLC, King of Prussia, Pennsylvania, USA.
  • Pharmacology & Toxicology, Research, CSL Limited, Melbourne, Victoria, Australia.
  • Pharmacology & Toxicology, Research, CSL Innovation GmbH, Marburg, Hesse, Germany. Electronic address: padmapriya.ponnuswamy@cslbehring.com.

Zitieren

APA

Schön, K., Pestel, S., Riedesel, J., Seyfert-Brandt, W., Claar, P., Herzog, E., Rezvani-Sharif, A., Ponnuswamy, P., & Nolte, M. W. (2024). Characterization of recombinant factor IX fusion proteins enabling subcutaneous administration. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.07.007

Vancouver

Schön K, Pestel S, Riedesel J, Seyfert-Brandt W, Claar P, Herzog E, et al. Characterization of recombinant factor IX fusion proteins enabling subcutaneous administration. Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2024.07.007

BibTeX
@article{Schn2024,
  author = {Schön, Kathrin and Pestel, Sabine and Riedesel, Julia and Seyfert-Brandt, Waltraud and Claar, Philipp and Herzog, Eva and Rezvani-Sharif, Alireza and Ponnuswamy, Padmapriya and Nolte, Marc W},
  title = {Characterization of recombinant factor IX fusion proteins enabling subcutaneous administration},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2024},
  doi = {10.1016/j.jtha.2024.07.007}
}
Kostenlos starten →